Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects

Bibliography

• Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett2002;12:2545-8
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L'Allier PL. Prevention of restenosis with antioxidants: mechanisms and implications. Am J Cardiovasc Drugs2002;2:323-34
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, Lavoie MA, L'Allier PL. Vascular protectants for the treatment of atherosclerosis. Expert Rev Cardiovasc Ther2003;1:385-92
   PubMedGoogle Scholar
• Ishizaka N, Kurokawa K, Taguchi J, et al. Inhibitory effect of a single local probucol administration on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis1995;118:53-6
   PubMed Web of Science ®Google Scholar
• Lau AK, Leichtweis SB, Hume P, et al. Probucol promotes functional reendothelialization in balloon-injured rabbit aortas. Circulation2003;107:2031-6
   PubMed Web of Science ®Google Scholar
• Schneider JE, Berk BC, Gravanis MB, et al. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation1993;88:628-37
   PubMed Web of Science ®Google Scholar
• Shinomiya M, Shirai K, Saito Y, Yoshida S. Inhibition of intimal thickening of the carotid artery of rabbits and of outgrowth of explants of aorta by probucol. Atherosclerosis1992;97:143-8
   PubMed Web of Science ®Google Scholar
• Kim MH, Cha KS, Han JY, et al. Effect of antioxidant probucol for preventing stent restenosis. Catheter Cardiovasc Interv2002;57:424-8
   PubMed Web of Science ®Google Scholar
• Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol2002;39:610-16
   PubMed Web of Science ®Google Scholar
• Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med1997;337:365-72
   PubMed Web of Science ®Google Scholar
• Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol1994;74:875-83
   PubMed Web of Science ®Google Scholar
• Watanabe K, Sekiya M, Ikeda S, et al. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J1996;132:23-9
   PubMed Web of Science ®Google Scholar
• Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol1997;30:855-62
   PubMed Web of Science ®Google Scholar
• Sekiya M, Funada J, Watanabe K, et al. Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. Am J Cardiol1998;82:144-7
   PubMed Web of Science ®Google Scholar
• Kunsch C, Luchoomun J, Grey JY, et al. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and antiinflammatory agent. J Pharm Exp Ther2004;308:820-9
   PubMed Web of Science ®Google Scholar
• Kunsch C, Qiu FH, Suen KL, et al. Inhibition of plasma oxidation and reduction of leukotriene B4 release after oral administration of AGI-1067, a novel anti-atherosclerotic agent. Atheroscler Suppl2007;8:185-6
   Web of Science ®Google Scholar
• Luyendyk JP, Piper JD, Tencati M, et al. A novel class of antioxidants inhibit LPS induction of tissue factor by selective inhibition of the activation of ASK1 and MAP kinases. Arterioscler Thromb Vasc Biol2007;27:1857-63
   PubMed Web of Science ®Google Scholar
• Wasserman MA, Sundell CL, Kunsch C, et al. Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Am J Cardiol2003;91:34-40A
   PubMed Web of Science ®Google Scholar
• Chilton A, Scott R, Liong SLW, Teng R. A pharmacokinetic study of the combined administration of AGI-1067, a novel antiatherosclerotic agent, and theophylline and warfarin in healthy subjects. Clin Pharmacol Ther2007;81:S107
   Google Scholar
• Chilton A, Scott R, Liong SLW, Teng R. A pharmacokinetic interaction study between AGI-1067, a novel antiatherosclerotic agent, and desipramine and digoxin in healthy subjects. Clin Pharmacol Ther2007;81:S107
   Google Scholar
• Sundell CL, Somers PK, Meng CQ, et al. AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, antiinflammatory and antiatherosclerotic agent. J Pharm Exp Ther2003;305:1116-23
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Jongsoon L, Goldfine AB. Inflammation and insulin resistance. J Clin Invest2006;116:1793-801
   PubMed Web of Science ®Google Scholar
• Tang C, Han P, Oprescu AI, et al. Evidence for a role of superoxide generation in glucose-induced β-cell dysfunction in vivo. Diabetes2007;56:2722-31
   PubMed Web of Science ®Google Scholar
• Gorogawa SI, Kajimoto Y, Umayahara Y, et al. Probucol preserves pancreatic β-cell function through reduction of oxidative stress in type 2 diabetes. Diabetes Res Clin Pract2002;57:1-10
   PubMed Web of Science ®Google Scholar
• Yoshino G, Matsushita M, Maeda E, et al. Effect of probucol on recovery from streptozotocin diabetes in rats. Horm Metab Res1992;24:306-9
   PubMed Web of Science ®Google Scholar
• Chen X, Dodd G, Sundell C, Kunsch C. AGI-1067, a novel antioxidant and antiinflammatory agent, inhibits activation of JNK, IRS-1 serine phosphorylation and production in adipocytes [poster]. Presented at the American Diabetes Association 68th Scientific Sessions, 6 – 10 June 2008, San Francisco, CA, USA Available from: www.atherogenics.com/science/invitroposter.pdf [Last accessed 14 November 2008]
   Google Scholar
• Sundell C, Fosgerau K, Chen X, et al. AGI-1067, a novel antioxidant and antiinflammatory agent, improves insulin sensitivity in a rat model of diet-induced obesity [poster]. Presented at the American Diabetes Association 68th Scientific Sessions, 6 - 10 June 2008, San Francisco, CA, USA. Available from: www.atherogenics.com/science/sundellposter.pdf [Last accessed 14 November 2008]
   Google Scholar
• Nomura S, Takahashi N, Inami N, et al. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis2004;174:329-35
   PubMed Web of Science ®Google Scholar
• Marathe GK, Prescott SM, Zimmerman GA, McIntyre TM. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med2001;11:139-42
   PubMed Web of Science ®Google Scholar
• Selley ML, Bartlett MR, Czeti AL, Ardlie NG. The role of (E)-4-hydroxy-2-nonenal in platelet activation by low density lipoprotein and iron. Atherosclerosis1998;140:105-12
   PubMed Web of Science ®Google Scholar
• Serebruany V, Malinin A, Scott R. The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease. J Cardiovasc Pharmacol Ther2006;11:191-6
   PubMed Web of Science ®Google Scholar
• Serebruany V, Malinin A, Qiu FH, et al. Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy. J Thromb Thrombolysis2008: published online 3 June 2008, doi:10.1007/s11239-008-0233-y
   Google Scholar
• Ogletree ML. Overview of physiological and pathophysiological effects of thromboxane A2. Fed Proc1987;46:133-8
   PubMedGoogle Scholar
• Tardif JC, Gregoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation2003;107:552-8
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L'Allier PL, et al. Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial. Atherosclerosis2008;197:480-6
   PubMed Web of Science ®Google Scholar
• Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med2003;349:1595-604
   PubMed Web of Science ®Google Scholar
• Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomized, double-blind, placebo-controlled trial. Lancet2008;371:1761-8
   PubMed Web of Science ®Google Scholar
• Davidson MH, Smith J, Scott R, et al. Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067. J Clin Lipidol2007;1:271-9
   PubMed Web of Science ®Google Scholar
• Atherogenics reports positive results from ANDES phase 3 clinical trial of AGI-1067 in type 2 diabetes [press release]. Atlanta, GA: AtheroGenics, Inc, July 2008. Available from: http://www.atherogenics.com/press/index.html [Last accessed 22 December 2008]
   Google Scholar
• Kris-Etherton PM, Lichtenstein AH, Howard BV, et al. Antioxidant vitamin supplements and cardiovascular disease. Circulation2004;110:637-41
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Rinninger F, Wang N, Ramakrishnan R, et al. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol 1999;19:1325-32
   Google Scholar
• Sundell CL, Turner S, Voogt J, et al. Succinobucol (AGI-1067) promotes reverse cholesterol transport in the rat through enhanced hepatic HDL-cholesterol uptake. J Clin Lipidol2007;1:319
   Google Scholar
• FDA News. FDA issues safety alert on Avandia. Available from: www.fda.gov/bbs/topics/NEWS/2007/NEW0163.html [Last accessed 23 December 2008]
   Google Scholar
• Nissen SE, Wolski K. Effects of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm2008;14:523-31
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective piolglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352:854-65
   PubMed Web of Science ®Google Scholar